RT Journal Article SR Electronic T1 Discovery of plasma protein biomarkers related to Alzheimer’s disease, sex and APOE genotype JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.15.20066647 DO 10.1101/2020.04.15.20066647 A1 Scott B. Laffoon A1 James D. Doecke A1 Anne M. Roberts A1 Jennifer A. Vance A1 Benjamin D. Reeves A1 Kelly K. Pertile A1 Rebecca L. Rumble A1 Chris J. Fowler A1 Brett Trounson A1 David Ames A1 Ralph Martins A1 Ashley I. Bush A1 Colin L. Masters A1 Paul A. Grieco A1 Edward A. Dratz A1 Blaine R. Roberts YR 2020 UL http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066647.abstract AB The Australian Imaging and Biomarker Lifestyle (AIBL) study of aging is designed to aid the discovery of biomarkers. The current study aimed to discover differentially expressed plasma proteins that could yield a blood-based screening tool for Alzheimer’s disease. To search for biomarkers and elucidate mechanisms of AD, we immuno-depleted the most abundant plasma proteins and pre-fractionated the remaining proteins by HPLC, prior to two-dimensional gel electrophoresis. The relative levels of approximately 3,400 protein species resolved on the 2D gels were compared using in-gel differential analysis with spectrally resolved fluorescent protein detection dyes (Zdyes™). Here we report on analysis of pooled plasma samples from an initial screen of a sex-matched cohort of 72 probable AD patients and 72 healthy controls from the baseline time point of AIBL. We report significant changes in variants of apolipoprotein E, haptoglobin, α1 anti-trypsin, inter-α trypsin inhibitor, histidine-rich glycoprotein, and a protein of unknown identity. α1 anti-trypsin and α1 anti-chymotrypsin demonstrated plasma concentrations that were dependent on APOE ε4 allele dose. Our analysis also identified an association with the level of Vitamin D binding protein fragments and complement factor I with sex. We then conducted a validation study on individual samples using a targeted LC-MS/MS assay. This study indicates that a peripheral protein signature has potential to aid in the characterization of AD. We also found significant associations of protein levels with APOE genotype, indicating that differences in genotype influence the circulating abundances of proteins other than ApoE.Competing Interest StatementEAD and PAG are founders and shareholders in Zdye LLC, which licenses patents issued to Montana State University and reagents used in the present study. BRR, SBL and EAD are inventors on PCT application AU2014/000849. BRR receives research support from Agilent Technologies and from eMSion Inc. (OR, USA). All other authors declare that no competing interests exist.Funding StatementWe would also like to acknowledge funding from the Dementia Collaborative Research Centres (DCRC), The Victorian Government’s Operational Infrastructure Support Program and the Wicking Trust. National Institutes of Health- Small Business Technology Transfer (NIH STTR grant 5R42RR021790, EAD PI), Center for Biological Research Excellence (NIH CoBRE grants 1P20RR024237 and 2P20GM 104935, EAD PI), Montana Board of Research and Commercialization Technology Grants: (MBRCT: 05-14, 06-46, and 08-17, EAD PI) and the Murdock Charitable Trust (EAD, PI). The Cooperative Research Centre for Mental Health, Alzheimer’s Drug Discovery Foundation grant (BRR, PI), Knott Family Equipment Grant (BRR, PI), the Pierce Armstrong Trust (BRR, PI), NHMRC Dementia Leadership Fellowship (BR, APP1138673), and NHMRC project grant (BR, APP1164692).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe proteomics data used to support the findings of this study are available from the corresponding author upon reasonable request.α1ATα1-Anti-trypsinα1ACTα1 Anti-chymotrypsinAPRAcute-phase reactantADAlzheimer’s diseaseAPPAmyloid precursor proteinAβAmyloid β peptideApoEApolipoprotein E proteinBBBBlood-brain barrierBMIBody mass indexCRPC-reactive proteinCNSCentral Nervous SystemCSFCerebrospinal fluidHptHaptoglobinHCHealthy controlHRGHistidine-rich glycoproteinITIHInter-α trypsin inhibitorIsoelectric point pIIsoelectric focusing IEFKPIKunitz-type protease inhibitorRP-HPLCReverse phase high pressure liquid chromatographyVDBPVitamin D binding proteinZAGZinc α 2-glycoprotein